Human CD126 ELISA Kit

Contact us
Diaclone
Product Code: 850.510.096
Product Group: ELISA Kits
Supplier: Diaclone
CodeSizePrice
850.510.0961 x 96 (pre-coated)£381.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Regulatory Status: RUO

Further Information

Antigen Synonyms:
gp80 /IL-6R
Assay Range:
31.25-1000 pg/ml
Cross reaction:
No cross reactivity with other human soluble receptors. No interference with neither soluble gp130 nor IL-6.
Description:
Diaclone ELISA Kits include pre-coated strip plates biotinylated secondary antibody standards controls (where applicable) buffers streptavidin-HRP TMB stop reagents and a detailed procedure.
Detection Target:
CD126 / gp80
Incubation:
1h45
Reactivity:
Human
Research Area:
Cytokine / Chemokine Receptors
Sample Size:
100 µl
Sample Types:
Serum Plasma Cell culture supernatant
Sensitivity:
5 pg/ml
Specificity:
Recognizes both natural and recombinant human soluble IL-6R

References

  1. Arranz-Valsero I. et al.Mol Vis.2013;19: 85-99. Involvement of corneal epithelial cells in the Th17 response in an in vitro bacterial inflammation model. https://www.ncbi.nlm.nih.gov/pubmed/23378722
  2. Burger R. et al. Haematologica. 2021 Sep 1; 106(9): 2507?2510. . Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth. https://pubmed.ncbi.nlm.nih.gov/33882638/
  3. Burger R. et al. Hematol J.2001; 2(1): 42-53.. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. https://www.ncbi.nlm.nih.gov/pubmed/11920233
  4. Corbi P. et al. Eur J Cardiothorac Surg. 2000; 18(1): 98 - 103. Circulating soluble gp130 soluble IL-6R and IL-6 in patients undergoing cardiac surgery with or without extracorporeal circulation. https://www.ncbi.nlm.nih.gov/pubmed/10869947
  5. Dore P. et al. Clin Exp Immunol.1997; 107(1): 182-8. IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases. https://www.ncbi.nlm.nih.gov/pubmed/9010274
  6. Gombocz K. et al. Crit Care2007; 11(4): R87. Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operations.. https://www.ncbi.nlm.nih.gov/pubmed/17697359
  7. Gougelet A. et al. PLoS One2009; 4(11): e8026. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody.. https://www.ncbi.nlm.nih.gov/pubmed/19956602
  8. Klausz K. et al.Oncotarget 2017 Sep 5;8(44):77552-77566.. A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.. https://www.ncbi.nlm.nih.gov/pubmed/29100408
  9. Le Meur Y. et al. Nephrol. Dial. Transplant. 1999; 14(10) : 2420 - 2426. Whole blood production of monocytic cytokines (IL-1beta IL-6 TNF-alpha sIL-6R IL-1Ra) in haemodialysed patients. https://www.ncbi.nlm.nih.gov/pubmed/10528667
  10. Leifsdottir KJ. et al. Neuroinflammation. 2018 Aug 8;15(1):223.. Fas-ligand and interleukin-6 in the cerebrospinal fluid are early predictors of hypoxic-ischemic encephalopathy and long-term outcomes after birth asphyxia in term infants.. https://www.ncbi.nlm.nih.gov/pubmed/30089504
  11. Puthier D. et al. Blood1996; 88(12): 4659-66. Myeloma cell growth arrest apoptosis and interleukin-6 receptor modulation induced by EB1089 a vitamin D3 derivative alone or in association with dexamethasone. https://www.ncbi.nlm.nih.gov/pubmed/8977259
  12. Santer F. R. et al. Endocr. Relat. Cancer 2010;17(1): 241-253.. Interleukin-6 trans-signalling differentially regulates proliferation migration adhesion and maspin expression in human prostate cancer cells. https://www.ncbi.nlm.nih.gov/pubmed/19966016
  13. Zekri A. R. et al. World J Gastroenterol.2005;11(42): 6624-30. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression.. https://www.ncbi.nlm.nih.gov/pubmed/16425355
  14. Zhang Z. Y. et al. Biomed Res Int. 2019; 2019: 1575468. . Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma. https://pubmed.ncbi.nlm.nih.gov/31915680/